| Literature DB >> 26956556 |
Sumanta Ray1, Sanghamitra Bandyopadhyay2.
Abstract
BACKGROUND: Predicting novel interactions between HIV-1 and human proteins contributes most promising area in HIV research. Prediction is generally guided by some classification and inference based methods using single biological source of information.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26956556 PMCID: PMC4784399 DOI: 10.1186/s12859-016-0952-6
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Fig. 1Overall summery of the proposed methodology
Fig. 2Figure shows the change of four topological metrics for randomly removal of nodes from the three networks viz., PPI network, coexpression network, and GO based semantic similarity network. For the three networks, change of four metrics: network density, average clustering coefficient, average degree of the network and average degree of the neighboring nodes are shown in panel (a), panel (b), panel (c) and in panel (d) respectively
Fig. 3Scale-free topology fitting index (R 2) at different threshold value (β) At β=9 the metric converges to 1. The red line signifies the value of β for which the network obeys scale free property
Fig. 4Integrating two categories of module into one matrix. The entry (g ,g ) in gene co-occurrence matrix is computed by performing the logical AND operation between two columns corresponding to g and g in the two layered clustering assingment matrix, and taking sum of this ANDing result
Fig. 5A toy example of identified meta-modules. It consists of HIV interacting and HIV non-interacting proteins. Among the non interacting set the prediction is performed
Fig. 6Statistical test to compare number of interactions among human proteins interacted with HIV-1 protein H in the predicted meta-modules
p-value obtained from Mann Whitney U test for each HIV protein
| HIV | Capsid | env_ | env_ | env_ | integrase | matrix | Nef | nucleocapsid | retropepsin | Rev | Tat | Vif | Vpr | Vpu | Pol | Gag_pr55 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| protein | gp120 | gp160 | gp41 | |||||||||||||
| name | ||||||||||||||||
|
| 0.0031 | 0.00091 | 0.02608 | 0.00903 | 0.0156 | 0.0183 | 0.082 | 0.0174 | 0.0071 | 0.0115 | 0.00030 | 0.0515 | 0.0200 | 0.1817 | 0.1606 | 0.0021 |
Fig. 7Scatter diagram for 10 selected meta modules showing the degree versus betweenness centrality of HIV-1 interacting proteins, HIV-1 non-interacting proteins, and the proteins that are predicted to interact with HIV-1 proteins. The three categories of proteins are represented by three separate markers
Predicted interactions supported by existing literature
| Sl. No. | HIV-1 protein | human Protein | PUBMED id |
|---|---|---|---|
| 1 | Env_gp41 | ITGA4 | PMID: 25008916 |
| 2 | Tat | MX2 | PMID: 24121441 |
| 3 | Tat | EBAG9 | PMID: 17250817 |
| 4 | Env_gp160 | ERGIC3 | PMID: 22190034 |
| 5 | Rev | HNRNPK | PMID: 19808671 |
| 6 | Rev | SNRPE | PMID: 11780068 |
| 7 | integrase | SUMO2 | PMID: 22895527 |
| 8 | Gag-matrix | BANF1 | PMID: 14645565 |
| 9 | Rev | HNRNPK | PMID: 19808671 |
| 10 | Env_gp120 | HLA-A | PMID: 1712812 |
| 11 | Env_gp120 | MSN | PMID: 9213396 |
| 12 | nucleocapsid | TOP1 | PMID: 21092135 |
| 13 | Tat | XBP1 | PMID: 10982343 |
| 14 | Env_gp120 | CD63 | PMID: 24507450 |
| 15 | Vpr | CASP8AP2 | PMID: 12095993 |
| 16 | Tat | H2AFZ | PMID: 18226242 |
| 17 | Tat | SOD1 | PMID: 24175971 |
| 18 | reverse transcriptase | ELAVL1 | PMID: 20459669 |
| 19 | Env_ gp120 | LGALS3BP | PMID: 24156545 |
| 20 | Vpr | PDHA1 | PMID: 23874603 |
| 21 | Env_gp120 | MAP2K2 | PMID: 15719026 |
| 22 | Vif | NEDD8 | PMID: 23300442 |
| 23 | Nef | VAMP3 | PMID: 20299515 |
| 24 | Env_gp120 | CD69 | PMID: 9604776 |
| 25 | Env_ gp120 | HLA-G | PMID: 25472996 |
| 26 | Tat | SEMA4D | PMID: 22134167 |
Fig. 8Proportion of predicted interactions involving HIV-1 proteins in five studies
Fig. 9Overlap of the predicted interaction sets of four literatures
Fig. 10Bar diagrams that show the distribution of interactions with p-values of the five predicted interaction sets. In each plot X-axis represents p-values while Y-axis represents proportion of interactions
GO and pathway enrichment of predicted meta modules
| Sl. No | No of genes | GO terms | KEGG pathway |
|---|---|---|---|
| 1 | 219 | translational elongation (1.5e-15) | Ribosome (6.7e-16) |
| 2 | 35 | positive regulation of transcription, DNA-dependent (2.8e-2) | not found |
| 3 | 248 | RNA processing (7.0E-8) | Ribosome (3.6e-4) |
| 4 | 29 | positive regulation of protein metabolic process (1.1e-3) | Proteasome (6.1e-3) |
| 5 | 205 | translational elongation (1.3E-28) | Ribosome (3.8E-21) |
| 6 | 32 | protein kinase cascade (5.1E-3) | Notch signaling pathway (9.7E-2) |
| 7 | 31 | regulation of actin filament polymerization (5.5E-3) | Cell cycle (5.7E-2) |
| 8 | 138 | regulation of programmed cell death (1.5E-5) | Natural killer cell mediated cytotoxicity (5.1E-4) |
| 9 | 133 | immune response (5.2E-8) | Allograft rejection (1.1E-5) |
| 10 | 106 | cell cycle (7.4E-6) | DNA replication (2.8E-4) |
| 11 | 92 | translational elongation (1.3E-21) | Ribosome (1.1E-19) |
| 12 | 89 | translational elongation (2.4E-15) | Ribosome (2.1E-13) |
| 13 | 80 | RNA splicing (3.1E-13) | Spliceosome (3.1E-5) |
| 14 | 82 | immune response (3.2E-3) | Regulation of actin cytoskeleton (4.9E-3) |
| 15 | 69 | chromatin modification (1.8E-2) | Cell cycle (2.2E-2) |
| 16 | 41 | regulation of cellular protein metabolic process (1.8E-4) | Huntington’s disease (2.1E-2) |
| 17 | 76 | electron transport chain (8.9E-5) | Parkinson’s disease (4.5E-9) |
| 18 | 68 | regulation of apoptotic process (2.7E-5) | T cell receptor signaling pathway (1.2E-2) |
| 19 | 66 | DNA metabolic process (1.9E-3) | Cell cycle (9.3E-2) |
| 20 | 40 | negative regulation of molecular function (1.9E-4) | not found |
| 21 | 72 | regulation of organelle organization (2.2E-3) | Fc gamma R-mediated phagocytosis (1.6E-2) |
| 22 | 64 | RNA splicing (2.9E-10) | Spliceosome (3.9E-9) |
| 23 | 62 | muscarinic acetylcholine receptor signaling pathway (7.5E-4) | Chemokine signaling pathway (1.4E-2) |
| 24 | 42 | RNA processing (7.5E-3) | Spliceosome (2.9E-2) |
| 25 | 68 | purine ribonucleoside monophosphate biosynthetic process (1.8E-3) | Ribosome (5.9E-3) |
| 26 | 24 | immune response (3.6E-4) | Aminoacyl-tRNA biosynthesis (7.8E-2) |
| 27 | 59 | regulation of DNA binding (4.0E-3) | Systemic lupus erythematosus (9.6E-3) |
| 28 | 27 | cellular defense response (5.6E-3) | Endocytosis (5.3E-2) |
| 29 | 183 | oxidative phosphorylation (7.9E-5) | Parkinson’s disease (6.9E-4) |
| 30 | 19 | negative regulation of macromolecule metabolic process (5.3E-2) | not found |